ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

J&J Provides Added Doxil Supply for Clinical Studies

By Peter Loftus Johnson & Johnson (JNJ) will provide additional supply of its cancer drug Doxil for use in clinical trials, including one testing whether the combination of an experimental Endocyte Inc. (ECYT) drug with Doxil improves treatment of ovarian cancer. Doxil has been in short supply since J&J's contract manufacturer experienced factory problems last year. Apart from affecting patients who were prescribed Doxil, the shortage also held up clinical trials of experimental drugs that were being tested with or against Doxil. J&J said Thursday it would provide supplies of Doxil to two clinical trials. One is a late-stage study testing whether Endocyte's EC145 and Doxil improves overall survival of women with ovarian cancer, versus Doxil alone. Endocyte said in a separate statement the additional Doxil would supplement an existing supply that was already in place to support the trial, and would allow the company to continue to enroll patients without interruption. Endocyte in April agreed to license EC145 to Merck & Co. (MRK), which gained global rights to develop and commercialize the drug in exchange for a $120 million up-front payment and up to $880 million in additional payments if certain milestones are met. Endocyte retains the right to co-promote the drug with Merck in the U.S. In addition, J&J will supply Doxil to be used in a clinical trial of VentiRx Pharmaceuticals' experimental cancer drug VTX-2337. J&J said its Doxil supplier, Boehringer Ingelheim's Ben Venue Laboratories unit, is making progress toward resuming production of Doxil near the end of this year. Ben Venue suspended production late last year as it tried to fix manufacturing problems identified by drug regulators. J&J has been allocating remaining supplies of Doxil through a rationing program. Earlier this year, the Food and Drug Administration approved the temporary importation of a replacement drug for Doxil, known as Lipodox. J&J said it will continue to pursue a shorter-term option to begin restoring Doxil supplies before the end of the year. Write to Peter Loftus at Subscribe to WSJ:

Stock News for Merck (MRK)
10/21/201621:57:00FDA Approves Merck’s ZINPLAVA™ (bezlotoxumab) to Reduce Recurrence of...
10/21/201606:45:00Merck’s KEYNOTE-045 Studying KEYTRUDA® (pembrolizumab) in Ad...
10/19/201607:00:00Merck Announces Pivotal Phase 3 Study of Letermovir, an Investigational...
10/17/201617:00:00Merck Research Laboratories Facilities Designated as “Milestones i...
10/14/201608:30:00Merck Launches Biosimilars Clarified, a New Online Educational...
10/10/201602:49:00Merck Announces Recipients of Third Annual €1 Million 'Grant f...
10/09/201602:44:00Study May Boost Use of Merck Lung-Cancer Drug
10/09/201602:16:00Two Major Studies to Be Presented at ESMO 2016 Congress Presidential...
10/09/201602:15:00KEYTRUDA® (pembrolizumab) Showed Continued Overall Survival...
10/08/201608:45:00Merck Announces Longer-Term Follow-Up of Overall Survival Data...
10/08/201602:15:00New KEYTRUDA® (pembrolizumab) Data in Advanced Urothelial Cancer...
10/07/201616:05:00Merck Animal Health Announces USDA Approval of Innovative Canine...
10/04/201618:03:00FDA Warns on Hepatitis C Drugs
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:53Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:26Statement of Changes in Beneficial Ownership (4)
10/04/201617:14:26Statement of Changes in Beneficial Ownership (4)
10/04/201616:10:00NewLink Genetics Awarded $25 Million Contract from BARDA for...
10/03/201623:00:00Samsung Affiliate Seeks European Approval for Herceptin Copy

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2016 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations